Soluble Therapeutics Acquired by CytoBioscience more

Young Living Essential Oils Partners with TFS Sandalwood Farms more

Beaufort Memorial Using Xenex Germ-Zapping Robot to Destroy Pathogens That Can Cause Hospital-Acquired Infections more

DNAtrix to Present Clinical Data at the 21st Annual Meeting of the Society for Neuro-Oncology more

Cartersville Medical Center Unveils Xenex Germ-Zapping Robot more

DNAtrix enters into license agreement with University of Florida to develop new oncolytic virus platform more

DNAtrix Licenses Myxoma Virus for New Immunotherapy Platform more

Supportive Data for the Use of Santalis Pharmaceuticals’ East Indian Sandalwood Oil (EISO) for the Treatment of Psoriasis is Presented at International Conference more

Santalis Pharmaceuticals Obtains FDA Allowance To Start A Phase 2 Clinical Study For The Treatment Of Mild To Moderate Atopic Dermatitis (AD)

SAN ANTONIO--(BUSINESS WIRE)--Following the recent start of its pediatric and adult Phase 2 clinical study for atopic dermatitis in Australia, Santalis Pharmaceuticals today announced it has obtained allowance from the U.S. Food and Drug Administration (FDA) to initiate a multi-center, placebo controlled, double blinded, Phase 2 efficacy and tolerability study for the treatment of mild to moderate atopic dermatitis (AD), also known as eczema. Patients must be 17 years of age or older with a clinically stable diagnosis of atopic dermatitis with a total body surface area (BSA) involvement of not more than 15%. Up to 72 patients will be enrolled to determine preliminary efficacy after 28 days of a twice-a-day treatment using a unique 5% East Indian Sandalwood Oil (EISO) cream formulation.

These Phase 2 studies follow on from a prior open-label study in the U.S., which demonstrated an over-the-counter formulation of EISO in combination with colloidal oatmeal to be safe, well tolerated, and efficacious for patients aged between 3 months and 12 years who had mild, moderate or severe eczema affecting a large percentage of their body surface area. The pharmaceutical-grade EISO from TFS Corporation Ltd. (Santalis’ parent company) has been demonstrated to inhibit a broad range of inflammatory and proliferative pathways thought to underlie this condition, including down-regulation of phosphodiesterase (PDE4) activity. In addition, EISO is effective in controlling many pathogens associated with secondary infections of AD, such as Staphlococcus aureus (“staph”).

“It’s very gratifying to have been given allowance to expand Santalis’ atopic dermatitis prescription drug development program into the U.S.,” said Frank Wilson, Managing Director of TFS Corporation. “We have invested significantly into developing the world’s only sustainable supply of cGMP produced, pharmaceutical-grade East Indian Sandalwood Oil, which is a unique botanical drug substance.”

“Atopic dermatitis continues to be difficult-to-treat condition affecting children and adults worldwide,” said Ian Clements, COO of Santalis Pharmaceuticals. “We now have an opportunity to further evaluate the unique range of pharmacological attributes of EISO in treating this important dermatological condition.”

About Atopic Dermatitis (AD)/Eczema
Atopic dermatitis is a chronic skin condition involving inflammation and itching. Drying of the skin is also very common. This disease is characterized by redness, swelling, weeping, cracking, crusting and scaling of the skin. Rubbing and scratching can lead to skin damage and secondary bacterial infections. Multiple factors can trigger the onset of, or worsen, atopic dermatitis, including low humidity, exposure to detergents or other chemicals, cold weather and seasonal allergies. Approximately 18 to 25 million people in the United States are believed to suffer from atopic dermatitis, with 80% to 90% having mild or moderate disease. It is estimated that the incidence of the disease amongst infants and children in the US is between 8% and 18%. Though most common in the pediatric population, about half of childhood cases carry over into adulthood. There is currently no cure for atopic dermatitis and current therapies are primarily palliative, focused on reduction of symptoms (redness, itching, etc.). Moisturizers, anti-inflammatory drugs, phototherapy and other approaches are often used. Long-term use of many of the current treatments is often not effective or can lead to complicating side effects.

ABOUT SANTALIS PHARMACEUTICALS
Santalis Pharmaceuticals, Inc. is a wholly­owned subsidiary of TFS Corporation, Ltd. (ASX: TFC). Santalis, and its sister company, Santalis Healthcare Corporation (formerly ViroXis Corp), were acquired by TFS in July 2015 and are developing scientifically and clinically validated over the counter and prescription products that utilize TFS’ cultivated, sustainable, pharmaceutical­grade East Indian Sandalwood Oil. Santalis’ product development programs are focused in dermatology and oral health, where EISO’s well documented safety and anti­infective, anti-proliferative and anti­inflammatory properties are well suited to a number of prevalent and under­served conditions. In addition to its Phase 2 AD studies, Santalis has ongoing Phase 2 clinical programs in pediatric Molluscum contagiosum, psoriasis and oral mucositis, and is preparing to initiate a Phase 3 study for HPV skin warts.

Contacts
Santalis Pharmaceuticals, Inc.
Ian Clements, COO, 210-399 2315
Mobile: 210-643 8847
Ian@santalispharma.com

Source: http://www.businesswire.com/news/ back

DNAtrix Announces First Patients Treated in Phase 2 Trial with DNX-2401 and KEYTRUDA more

Robotics: Germ-Zappers Are Saving Lives more

DHR first in RGV with xenon UV disinfection systems more

neoSurgical® Announces CE Mark Approval of the neoClose® Laparoscopic Port Closure Device more

Germ-zapping robot named 'Gronk' helped kill MRSA at Mass. high school more

Doctors Hospital at Renaissance is First in Rio Grande Valley to Deploy Xenex Germ-Zapping Robots more

Bio2 Medical's Angel Catheter successfully placed in first two patients more

Cardiovate Develops First Bioabsorbable Vascular Graft more

Funding San Antonio’s Biotech Ecosystem more

A biotech groups to share in major military contract to manufacture stem cells more

Robot disinfecting rooms at Life Line Hospital in Wintersville more

Life Line Hospital is the First Long Term Acute Care Hospital in Ohio to Enhance Patient Safety by Deploying a Xenex Germ-Zapping Robot more

Robots show Marin, Sonoma hospitals the light on disinfection more

Santalis Pharmaceuticals Announces Issuance of Patent for the Use of Sandalwood Oil to Treat Cancers more

Santalis Pharmaceuticals Initiates a Phase 2 Study of Mild, Moderate and Severe Atopic Dermatitis - Enrolls First Patient Into Its Australian Clinical Trial Site more

With Scaffold for Regenerating Arteries, Cardiovate Raises $350,000 more

Bluegrass Vascular Secures CE Mark Approval and Announces Successful Commercial Use of The Surfacer® Inside-Out® Access Catheter System more

Bio2 Medical® Closes on $3 Million of Venture Debt Financing more

Tropical Forestry Services prepares for first Indian sandalwood shipment to China more

Bio2 Medical® Announces 510(k) Clearance from the FDA for the Angel® Catheter, the First Ever Prophylactic Use Indication for a Medical Device for Pulmonary Embolism more

International perfumery competition winner tours Indian sandalwood plantations in the Kimberley more

SA biotech firm drawing global interest year after moving from Germany more

TFS Corporation makes bond offer more

New robot system at USC Verdugo Hills Hospital uses UV light to disinfect hospital rooms more

DNAtrix wins $2 million FDA grant for cancer immunotherapy more

DNAtrix Awarded FDA Orphan Products Development Grant for DNX-2401 more

TFS Corporation - July 2016 Update more

StemBioSys reaches European distribution agreement for its products more

BRIEF-Diamyd Medical: Cellaviva appointed European distributor for StemBioSys more

DNAtrix Receives European Medicines Agency PRIME Designation more

DNAtrix Announces Successful Intratumoral Delivery of DNX-2401 via Alcyone's MEMS Cannula for the Targeted Treatment of Recurrent Glioblastoma more

Australia forestry company TFS Corp gets two ratings upgrades more

Tour of Texas: Valence, Stellarray, Flux Farms, A&M, StemBioSys more

StemBioSys reaches distribution agreement for its products in South Korea more

Camden Clark Medical Center Introduces Newest Xenex Germ-Zapping Robot more

MPR Client Innovative Trauma Care Wins Gold at 2016 Medical Design Excellence Awards more

Santalis Pharmaceuticals Announces Positive Results From a Study Using 10% East Indian Sandalwood Oil (EISO) Serum Formulation for the Treatment of Mild-to-Moderate Plaque Psoriasis more

Texas among top states in foreign investments more

How Your Family Drives Business Decisions more

StemBioSys enters distribution agreement for its products in Japan more

San Antonio biotech firm takes big step toward global expansion more

Vidant Edgecombe Hospital adds Xenex Germ-Zapping Robot to reduce HAIs more

This hospital spent $300,000 on giant, superbug-killing robots more

Santalis Announces First Subject Enrolled in Phase 2 Trial of East Indian Sandalwood Oil (EISO) to Treat Mild to Moderate Plaque Psoriasis more

SA biotech company backing fed stem cell bill to cut red tape from regulatory pathway more

Bexar County added 4,350 jobs last year, study says more

Springfield Clinic unveils Xenex Germ-Zapping Robot for infection control more

San Antonio venture capital funding fell last year more

neoSurgical Limited Expands Indications For neoClose Device more

Bio2 Medical Closes Series D Preferred Stock more

TFS undertakes $60 million placement more

Bluegrass Vascular Technologies’ catheter system used on first patient more

Cytocentrics refunds $100,000 in economic development funds to city more

Bluegrass Vascular Technologies Announces First Clinical Use of the Surfacer® Inside-Out® Access Catheter System in Europe. more

Long-term acute care facility in California implements Xenex germ-zapping robot more

Robotic housekeeper disinfects the rooms at Modesto hospital more

Aerin Medical raises $16.7M, adds new board members more

Brokers Sniff Sweet Potential In TFS Corp more

East Indian sandalwood oil (EISO) is the key ingredient in these grooming products for dogs more

Santalis Pharmaceuticals Completes the Spin-Off of Roxy’s Remedies Inc. more

TFS Corporation - January 2016 Update more

DNAtrix's Oncolytic Immunotherapy, DNX-2401, Awarded EU Orphan Medicine Designation more

Strategic partnering deal with Cytocentrics more

Cytocentrics CEO: San Antonio to get big boost from new deal more

GhostBuster the Lab Mix Reviews Roxy’s Remedies Pure Relief Spray Gel more

Avera McKennan Addresses Patient Safety with Germ-Zapping Robots more

Santalis Pharmaceuticals Announces Positive Results from a Study of Pediatric Patients with Eczema more

Santalis announces positive results for pediatric atopic dermatitis treatment more

Here’s why the TFS Corporation Limited share price soared 28% today more

Cytocentrics gaining traction in San Antonio more

The Drugstore Acne Fighters Dermatologists Swear By more

neoSurgical® Begins Postmarket Surveillance Study more

Santalis Announces First Subject Enrolled in Phase 2 Trial more

BiO2 Medical Reports Positive Advancement of the Series D Round of Funding more

Germany’s Axiogenesis to collaborate with new San Antonio biotech company more